The authors concluded that the third-generation regimens had comparable response rates for chemotherapy-naive patients with advanced non-small cell lung cancer, but produced different rates of disease control. These conclusions appear to reflect the findings, but a lack of reporting of the review methods and no assessment of trial quality make it difficult to confirm their reliability.
Study selection
Phase II or III trials involving patients with pathologically proven advanced NSCLC, with no previous treatment for metastatic disease, and random allocation between a two-drug regimen containing at least one third-generation drug (gemcitabine, vinorelbine, docetaxel, or paclitaxel) and a two-drug combination without the third-generation drug, were eligible for inclusion. Both platinum (cisplatin or carboplatin) and non-platinum combinations were eligible. Trials had to report the response or the progressive-disease rate and the number of patients in each treatment arm. Trials were excluded if they: included irinotecan; compared cisplatin with carboplatin; or used combinations that included biological drugs.
Where reported, the median age ranged from 56 to 72.5 years and the percentage of men ranged from 51 to 93. Most of the patients had NSCLC at stage IIIB or IV. Most of them had not had chemotherapy. Most of the trials assessed response using World Health Organization criteria.
